Bradykinin b2-receptor blockade facilitates deoxycorticosterone-salt hypertension

Paolo Madeddu, Paolo Pinna Parpaglia, Maria Piera Demontis, Maria Vittoria Varoni, Maria Caterina Fattaccio, Giancarlo Tonolo, Chiara Troffa, Nicola Glorioso

Research output: Contribution to journalArticlepeer-review


The contribution of endogenous kinins to the regulation of blood pressure, urinary volume, and renal sodium excretion was evaluated in Wistar rats on higb sodium intake by using the new bradykinin receptor antagonist Hoe 140 (D-Arg,[Hyp’, This, D-Tic7, Oic']-bradykinin). Neither Hoe 140 (3 nmol/hr s.c. for 4 weeks) nor its vehicle altered systolic blood pressure (tail-cuff plethysmography) or renal (Unction in rats given saline solution (0.15 mol/L NaCI) to drink ad libitum. Four-week administration of deoxycorticosterone (DOC), combined with high sodium intake and uninephrectomy, increased systolic blood pressure from 127±3 to 160±3 mm Hg (p

Original languageEnglish
Pages (from-to)980-984
Number of pages5
Issue number6
Publication statusPublished - 1993


  • Blood pressure
  • Bradykinin
  • Kallikrein
  • Kinins
  • Mineralocorticoids

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Bradykinin b2-receptor blockade facilitates deoxycorticosterone-salt hypertension'. Together they form a unique fingerprint.

Cite this